SCHEMBL5137571

SCHEMBL5137571

CCCCN(Cc1cccc(OC)c1)Cc1c(-c2ccc(Cl)cc2)nc(-c2ccccc2)n1CCCC

nearest known ligand 0.44

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
POLB P06746 1/20 0.42
RXFP1 Q9HBX9 1/20 0.42
C5AR1 P21730 1/20 0.41
CALM1 P0DP23 1/20 0.41
CAMKK2 Q96RR4 1/20 0.41
TLR7 Q9NYK1 1/20 0.40
USP2 O75604 5/20 0.39
ALDH1A1 P00352 4/20 0.39
HSD17B10 Q99714 4/20 0.39
CASP1 P29466 4/20 0.39
CASP7 P55210 4/20 0.39
CYP1A2 P05177 3/20 0.39
CYP2C19 P33261 3/20 0.39
MAPK1 P28482 2/20 0.39
HIF1A Q16665 2/20 0.39
CYP3A4 P08684 3/20 0.38
LMNA P02545 3/20 0.38
CYP2C9 P11712 2/20 0.38
TP53 P04637 2/20 0.38
TSHR P16473 1/20 0.38

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL5135705 0.95 CALM1 (0.45) C5AR1CALM1CAMKK2TLR7TSHR
SCHEMBL5170566 0.94 CALM1 (0.43) C5AR1CALM1CAMKK2TLR7ALDH1A1
SCHEMBL5135794 0.93 TSHR (0.42) POLBC5AR1ALDH1A1HSD17B10LMNA
SCHEMBL5134931 0.92 CALM1 (0.44) C5AR1CALM1CAMKK2TLR7ALDH1A1
SCHEMBL5072289 0.92 ABCB1 (0.42) C5AR1CALM1CAMKK2TLR7USP2
SCHEMBL5137491 0.91 CALM1 (0.45) C5AR1CALM1CAMKK2TLR7USP2
SCHEMBL5074293 0.91 CALM1 (0.45) C5AR1CALM1CAMKK2TLR7USP2
SCHEMBL5135329 0.91 TP53 (0.46) C5AR1ALDH1A1HSD17B10LMNATP53
SCHEMBL5167256 0.90 C5AR1 (0.44) C5AR1TLR7ALDH1A1TSHRCRHR1
SCHEMBL5137893 0.90 C5AR1 (0.43) C5AR1TP53TSHRCRHR1TSPO

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1490044-A4 COMBINATION THERAPY FOR THE TREATMENT OF CONDITIONS WITH PATHOGENIC INFLAMMATORY COMPONENTS NEUROGEN CORP (US) 2008-04-16 EP disclosed
EP-1490044-A1 COMBINATION THERAPY FOR THE TREATMENT OF CONDITIONS WITH PATHOGENIC INFLAMMATORY COMPONENTS NEUROGEN CORPORATION (US) 2004-12-29 EP disclosed
WO-2003084524-A1 COMBINATION THERAPY FOR THE TREATMENT OF CONDITIONS WITH PATHOGENIC INFLAMMATORY COMPONENTS NEUROGEN CORPORATION (US) 2003-10-16 WO disclosed